Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
K03QGcdvSK2NJh1J
Listen
